A Model for NAD(P)H: Quinoneoxidoreductase 1 (NQO1) Targeted Individualized Cancer Chemotherapy-Reference-Cited by-同舟云学术

A Model for NAD(P)H: Quinoneoxidoreductase 1 (NQO1) Targeted Individualized Cancer Chemotherapy

Published:2009-01 Issue: Volume:4 Page:DTI.S1146
ISSN:1177-3928
Container-title:Drug Target Insights
language:en
Short-container-title:Drug Target�Insights

Author:

Begleiter Asher¹,El-Gabalawy Nadia²,Lange Laurie²,Leith Marsha K.²,Guziec Lynn J.³,Guziec Frank S.³

Affiliation:

1. Manitoba Institute of Cell Biology, CancerCare Manitoba, Departments of Internal Medicine and Pharmacology and Therapeutics, University of Manitoba, 675 McDermot Avenue, Winnipeg, Manitoba R3E 0V9 Canada.

2. Manitoba Institute of Cell Biology, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, Manitoba R3E 0V9 Canada.

3. Department of Chemistry and Biochemistry, Southwestern University, Georgetown, Texas 78628 U.S.A.

Publisher

Aboutscience Srl

Subject

Pharmacology (medical),Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.4137/DTI.S1146

Reference45 articles.

1. DT-diaphorase and cancer chemotherapy

2. The experimental development of bioreductive drugs and their role in cancer therapy

3. Cellular pharmacology of quinone bioreductive alkylating agents

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer-Specific hNQO1-Responsive Biocompatible Naphthalimides Providing a Rapid Fluorescent Turn-On with an Enhanced Enzyme Affinity;Sensors;2019-12-20

2. A small molecule chaperone rescues the stability and activity of a cancer‐associated variant of NAD(P)H:quinone oxidoreductase 1in vitro;FEBS Letters;2019-10-30

3. A coumarin-naphthalimide hybrid as a dual emissive fluorescent probe for hNQO1;Dyes and Pigments;2019-05

4. Catalytic competence, structure and stability of the cancer‐associated R139W variant of the human NAD (P)H:quinone oxidoreductase 1 ( NQO 1);The FEBS Journal;2017-03-17

5. Impact of Tumor Blood Flow Modulation on Tumor Sensitivity to the Bioreductive Drug Banoxantrone;Journal of Pharmacology and Experimental Therapeutics;2012-11-28